PETACH TIKVA, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that the parties have agreed on the terms and conditions pursuant to which Nanox will acquire VasoHealthcare IT Inc. (“VHC IT”) from Vaso Corporation (“Vaso”) (OTCQX: VASO), subject to certain conditions.
This transaction is intended to accelerate deployment of Nanox’s AI solutions across U.S. healthcare facilities and is expected to be executed and completed within a couple of weeks.
VHC IT is a healthcare information technology provider serving hospitals and healthcare providers across the United States, with a team of professionals specializing in healthcare IT implementation. Its capabilities include healthcare systems integration, workflow optimization, data migration, user training, and nationwide go-live support for medical imaging.
Ad Statistics
Times Displayed: 346960
Times Visited: 21062 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
Under the terms of the proposed acquisition, VHC IT’s established operational and customer-support infrastructure will be integrated with Nanox.AI’s FDA-cleared AI solutions that analyze routine CT scans for indicators of chronic diseases. This integration, once completed, will enable faster deployment and adoption while reducing time-to-value for healthcare providers. VHC IT team’s, expertise and long-standing customer relationships are expected to support the Company’s U.S. commercial expansion.
Under the terms of the proposed transaction, Nanox will acquire VHC IT for a total consideration of up to $800,000, consisting of a $200,000 cash payment at closing and up to $600,000 in performance-based earnout payments over a period of up to two years, contingent upon revenue retention targets with respect to existing customers.
“As we scale our AI business in the U.S., deployment pace and implementation quality are critical to success,” said Erez Meltzer, CEO and Acting Chairman of Nanox. “Bringing these capabilities in-house will allow us to control the entire customer experience—from software delivery through go-live support. This acquisition will accelerate our ability to onboard new customers quickly and efficiently.”
Dr. Jun Ma, President and Chief Executive Officer of Vaso, said, “We believe that upon its execution, this transaction will be a positive development for our shareholders and will provide a strong future for the VasoHealthcare IT team as part of Nanox.”
About Nanox.AI
Nanox.AI is the deep-learning medical imaging analytics subsidiary of Nanox. Nanox.AI solutions are developed to target highly prevalent chronic and acute diseases affecting large populations around the world. Leveraging AI, Nanox.AI helps clinicians extract valuable and actionable clinical insights from medical imaging that otherwise may go unnoticed, potentially initiating further medical assessment to establish individual preventative care pathways for patients. For more information, please visit www.nanox.vision/ai.
